Awards as PI
| Funding | ||
|---|---|---|
| Targeted Clinical Development | Evaluation of Safety and Preliminary Efficacy of Escalating Doses of GRNOPC1 in Subacute Spinal Cord Injury | $24,846,856 |
| Disease Team Therapy Planning I | Preclinical Development and First-In-Human Testing of [REDACTED] in Advanced Heart Failure | $106,239 |
Total: $24,953,095.00 |
